Quantcast

Latest Mylan Inc. Stories

2014-04-03 16:23:55

PITTSBURGH, April 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of U.S. Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013. The final rejection issued today finds the first claim of the reissue application, which is identical to the only claim in...

2014-03-31 16:26:53

PITTSBURGH, March 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced that today the Supreme Court of the United States granted certiorari in Mylan's patent litigation against Teva relating to Mylan's Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone). In July of 2013, the Court of Appeals for the Federal Circuit ruled that Teva's U.S. Patent No. 5,800,808 ("the '808 patent"), along with other patents, was invalid as indefinite. The Supreme Court...

2014-03-27 08:33:44

Jury awards Mylan $106.7 million in damages PITTSBURGH, March 27, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. The jury decided that GSK owes Mylan $106.7 million in damages. Mylan's claims were based...

2014-03-24 12:31:14

PITTSBURGH, March 24, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all patents asserted by Mylan, protecting Perforomist® (formoterol fumarate) Inhalation Solution. Mylan previously sued Teva alleging that Teva's Abbreviated New Drug Application (ANDA) for this product infringed four Mylan patents covering Perforomist. After a full trial, the Court...

2014-03-13 08:28:09

PITTSBURGH, March 13, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the United States District Court for the Eastern District of Virginia has ruled invalid a patent, United States Patent No. RE44,048, related to Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Mylan was sued by G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for alleged infringement of this patent in connection with Mylan's Abbreviated New Drug Application (ANDA) for...

2014-03-11 16:26:19

PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including...

2014-03-11 16:26:16

Company launches anti-fungal AmBisome® as one of the segment's first product offerings MUMBAI, India and PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome(®), a leading...

2014-02-28 08:25:44

PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, in Miami. The presentation is scheduled to begin at 2:00 p.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An...

2014-02-28 08:25:10

PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014, in Boston. The presentation is scheduled to begin at 8:40 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-02-27 08:29:14

Provides 2014 Adjusted Diluted EPS Guidance Range of $3.25 - $3.60 and 2014 Revenue Guidance of $7.8 billion - $8.2 billion, Representing Year-Over-Year Growth of 19% and 16%, Respectively PITTSBURGH, Feb. 27, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2013. Financial Highlights -- Adjusted diluted EPS of $0.78 for the three months ended December 31, 2013 compared to $0.65 for the same...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related